FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Inovio reports clinical success for cervical cancer vax


Inovio Pharmaceuticals says its DNA cervical cancer vaccine produced promising results in an early-stage study, with one dose group registering "unprecedented T-cell responses" for five out of six patients. The vaccine company says that VGX-3100, its vaccine to treat precancerous cervical dysplasias and cervical cancers caused by human papillomavirus types 16 and 18, will be ready to go into Phase II in the first quarter of next year. Inovio release

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about cervical cancer   Inovio BioMedical  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.